Ahmed valve implantation results in neovascular glaucoma patients: Evaluation of short-term and remote

Abstract

Objective: to evaluate Ahmed valve implantation results in neovascular glaucoma patients. Methods: standard implantation method was used in 87 patients aged 57-86 years. Check-up examinations were performed in 1 week, 1, 3, 6, 9, 12 and 36 months after surgery. Results: during short-term post-op period (one month after surgery), intraocular pressure normalized in 48 patients. During remote post-op period (6-36 months after surgery), intraocular pressure normalization was achieved in 69 patients (79.2 %), among them in 62 patients (71.2 %) - against the background of IOP-lowering treatment. The main complication was a hemorrhage from anterior chamber angle and iris new vessels that was found in 37 patients (42.5 %), in a quarter of cases it required hyphema washout. In three patients, sustained hypotony developed, in one case it brought to globe sub-atrophy. In two of observed patients, enucleation was performed because of pain syndrome rebound. Conclusions: In 79.2 % neovascular glaucoma patients, the valve implantation led to IOP normalization, while in 71.2 % of cases it required a return to IOP-lowering therapy.

Keywords

neovascular glaucoma / surgical treatment / Ahmed valve / complications

References

[1] Егорова Э. В., Буссарабов А. Н., Дробница А. А. Прогнозирование результатов контактной транссклеральной диод-лазерной циклофотокоагуляции на основе оценки исходного состояния ЦТ у больных с терминальной болящей глаукомой методом ультразвуковой биомикроскопии. Сборник научных статей XI международного конгресса Глаукома: теории, тенденции, технологии.»HRT клубРоссия-2013».М.;2013:125-129.

[2] Кушнир В. Н., Русу А. А., Кушнир В. В. Неоваскулярная глаукома - проблемы лечения и пути их возможного решения. Клиническая офтальмология. 2011; 12 (4): 129-130.

[3] Chang S. H., Chen Y. C., Li C. Y., Wu S. C. Contact diode laser transscleral cyclophotocoagulation for refractory glaucoma: comparison of two treatment protocols. Can J Ophthalmol. 2004; 39 (5): 511-516.

[4] Chen H. E., Chen M. C., Lai C. C., Yeung L., Wang N. K., Chen H. S., Ku W.C., Wu S. C., Chang S. H., Chuang L. H. Neovascular glaucoma after central retinal vein occlusion in preexisting glaucoma. BMC Ophthalmol.2014; 14 (1): 119.

[5] Horsley M. B., Kahook M. Y. Anti-VEGF therapy for glaucoma. Curr Opin Ophthalmol. 2010; 21 (2): 112-117.

[6] Iliev M. E., Gerber S. Long-term outcome of transscleral diode laser cyclophotocoagulation in refractory glaucoma. Br J Ophthalmol. 2007; 91 (12):1631-1635.

[7] Li Z., Zhou M., Wang W., Huang W., Chen S., Li X., Gao X., Zhang X. A prospective comparative study on neovascular glaucoma and nonneovascular refractory glaucoma following Ahmed glaucoma valve implantation. Chin Med J. (Engl). 2014;127 (8):1417-1422.

[8] Martinez-Carpio P. A., Bonafonte-Marquez E., Heredia-Garcia C. D., Bonafonte-Royo S. Efficacy and safety of intravitreal injection of bevacizumab in the treatment of neovascular glaucoma: systematic review. Arch Soc Esp Oftalmol. 2008; 83 (10):579-588.

[9] Nakatake S., Yoshida S., Nakao S., Arita R., Yasuda M., Kita T., Enaida H., Ohshima Y., Ishibashi T. Hyphema is a risk factor for failure of trabeculectomy in neovascular glaucoma: a retrospective analysis. BMC Ophthalmol. 2014; 14: 55.

[10] Ryu C. L., Elfersy A., Desai U., Hessburg T., Edwards P., Gao H. The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis. J Ophthalmol.2014:317694

[11] Sevim M. S., Buttanri I. B., Kugu S., Serin D., Sevim S. Effect of intravitrealbevacizumab injection before Ahmed glaucoma valve implantation in neovascular glaucoma. Ophthalmologica. 2013; 229 (2):94-100.

[12] Shen C. C., Salim S., Du H., Netland P. A. Trabeculectomy versus Ahmed Glaucoma Valve implantation in neovascular glaucoma. Clin Ophthalmol. 2011; 5: 281-286.

[13] Tatsumi T., Yamamoto S., Uehara J., Sugawara T., Baba T., Inoue M., Hata H., Mitamura Y. Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma. Graefes Arch Clin Exp Ophthalmol. 2013; 251 (5):1355-1360.

[14] Wakabayashi T., Oshima Y., Sakaguchi H., Ikuno Y., Miki A., Gomi F., Otori Y., Kamei M., Kusaka S., Tano Y. Intravitreal bevacizumab to treat iris neovascularization and neovascular glaucoma secondary to ischemic retinal diseases in 41 consecutive cases. Ophthalmology. 2008; 115 (9):1571-1580.

[15] Zhang H. T., Yang Y. X., Xu Y. Y., Yang R. M., Wang B. J., Hu J. X. Intravitreal bevacizumab and Ahmed glaucoma valve implantation in patients with neovascular glaucoma. Int J Ophthalmol. 2014; 7 (5): 837-842.

RIGHTS & PERMISSIONS

Pavlova O.G., Nikolaenko V.P.